Patents by Inventor Charles M. Rice
Charles M. Rice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110318730Abstract: Cell cultures are provided that include a population of micropatterened hepatocytes and one or more non-parenchymal cell populations, where the hepatocytes are infected with a virus or parasite and include a reporter of virus or parasite infection. Methods of making and using the cell cultures are also provided.Type: ApplicationFiled: July 7, 2009Publication date: December 29, 2011Applicants: THE ROCKEFELLER UNIVERSITY, MASS INSTITUTE OF TECHNOLOGYInventors: Charles M. Rice, III, Christopher Thomas Jones, Alexander Ploss, Sangeeta N. Bhatia, Salman Khetani
-
Patent number: 7794942Abstract: HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier. Additionally, methods for inducing immunoprotection to HCV in a primate are described, as are methods for testing a compound for inhibiting HCV replication.Type: GrantFiled: December 19, 2007Date of Patent: September 14, 2010Assignee: Washington UniversityInventors: Charles M. Rice, Keril J. Blight
-
Patent number: 7455969Abstract: This invention relates generally to cells and cell lines that are permissive for hepatitis C virus (HCV) replication, and methods and materials for making and using them. The subject cell line referred to as Huh-7.5 has the A.T.C.C. designation number PTA-8561, having been deposited on Aug. 1, 2007.Type: GrantFiled: November 13, 2003Date of Patent: November 25, 2008Assignee: Washington UniversityInventors: Charles M. Rice, III, Keril J. Blight
-
Publication number: 20080213750Abstract: HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier. Additionally, methods for inducing immunoprotection to HCV in a primate are described, as are methods for testing a compound for inhibiting HCV replication.Type: ApplicationFiled: December 19, 2007Publication date: September 4, 2008Applicant: WASHINGTON UNIVERSITYInventors: Charles M. Rice, Keril J. Blight
-
Patent number: 7407758Abstract: HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are methods for identifying HCV variant polynucleotides with increased transfection efficiencies. Additionally, methods for identifying one or more HCV sequence mutations that provide drug-resistant HCV variants are disclosed.Type: GrantFiled: July 1, 2005Date of Patent: August 5, 2008Assignee: Washington UniversityInventors: Charles M. Rice, III, Keril J. Blight
-
Patent number: 7338759Abstract: HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier. Additionally, methods for inducing immunoprotection to HCV in a primate are described, as are methods for testing a compound for inhibiting HCV replication.Type: GrantFiled: May 23, 2001Date of Patent: March 4, 2008Assignee: Washington UniversityInventors: Charles M. Rice, Keril J. Blight
-
Patent number: 7235394Abstract: The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e.g., for gene therapy of gene vaccines.Type: GrantFiled: November 6, 2003Date of Patent: June 26, 2007Assignee: Washington UniversityInventors: Charles M. Rice, Alexander A. Kolykhalov
-
Patent number: 7049428Abstract: HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier. Additionally, methods for inducing immunoprotection to HCV in a primate are described, as are methods for testing a compound for inhibiting HCV replication.Type: GrantFiled: May 23, 2000Date of Patent: May 23, 2006Assignee: Washington UniversityInventors: Charles M. Rice, III, Keril J. Blight
-
Patent number: 6943246Abstract: The invention relates to the discovery of a novel RNA sequence at the 3? terminal sequence of hepatitis C virus (HCV) genome RNA. Included in the invention are the 3? sequence, its complement, and their use for nucleic-acid based diagnostics and for developing and evaluating novel anti-HCV therapies. This sequence element, which is conserved among HCV genotypes, is likely to be essential for viral replication, and required for construction of full-length HCV cDNA clones capable of yielding infectious RNA, progeny virus or replication-competent HCV replicons. Such functional clones are useful tools for evaluation of therapeutic approaches and as substrates for developing candidate attenuated or inactivated HCV derivatives for vaccination against HCV.Type: GrantFiled: May 30, 2002Date of Patent: September 13, 2005Assignee: Washington UniversityInventors: Charles M. Rice, Alexander A. Kolykhalov
-
Publication number: 20030073080Abstract: The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e.g., for gene therapy of gene vaccines.Type: ApplicationFiled: July 27, 2001Publication date: April 17, 2003Applicant: Washington UniversityInventors: Charles M. Rice, Alexander A. Kolykhalov
-
Publication number: 20030054341Abstract: The invention relates to the discovery of a novel RNA sequence at the 3′ terminal sequence of hepatitis C virus (HCV) genome RNA. Included in the invention are the 3′ sequence, its complement, and their use for nucleic-acid based diagnostics and for developing and evaluating novel anti-HCV therapies. This sequence element, which is conserved among HCV genotypes, is likely to be essential for viral replication, and required for construction of full-length HCV cDNA clones capable of yielding infectious RNA, progeny virus or replication-competent HCV replicons. Such functional clones are useful tools for evaluation of therapeutic approaches and as substrates for developing candidate attenuated or inactivated HCV derivatives for vaccination against HCV.Type: ApplicationFiled: May 30, 2002Publication date: March 20, 2003Inventors: Charles M. Rice, Alexander A. Kolykhalov
-
Publication number: 20030028010Abstract: The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e.g., for gene therapy of gene vaccines.Type: ApplicationFiled: November 28, 2001Publication date: February 6, 2003Applicant: Washington UniversityInventors: Charles M. Rice, Alexander A. Kolykhalov
-
Publication number: 20030027130Abstract: The invention relates to the discovery of a novel RNA sequence at the 3′ terminal sequence of hepatitis C virus (HCV) genome RNA. Included in the invention are the 3′ sequence, its complement, and their use for nucleic-acid based diagnostics and for developing and evaluating novel anti-HCV therapies. This sequence element, which is conserved among HCV genotypes, is likely to be essential for viral replication, and required for construction of full-length HCV cDNA clones capable of yielding infectious RNA, progeny virus or replication-competent HCV replicons. Such functional clones are useful tools for evaluation of therapeutic approaches and as substrates for developing candidate attenuated or inactivated HCV derivatives for vaccination against HCV.Type: ApplicationFiled: June 13, 2001Publication date: February 6, 2003Applicant: Washington UniversityInventors: Charles M. Rice, Alexander A. Kolykhalov
-
Publication number: 20030017586Abstract: The invention relates to the discovery of a novel RNA sequence at the 3′ terminal sequence of hepatitis C virus (HCV) genome RNA. Included in the invention are the 3′ sequence, its complement, and their use for nucleic-acid based diagnostics and for developing and evaluating novel anti-HCV therapies. This sequence element, which is conserved among HCV genotypes, is likely to be essential for viral replication, and required for construction of full-length HCV cDNA clones capable of yielding infectious RNA, progeny virus or replication-competent HCV replicons. Such functional clones are useful tools for evaluation of therapeutic approaches and as substrates for developing candidate attenuated or inactivated HCV derivatives for vaccination against HCV.Type: ApplicationFiled: June 13, 2001Publication date: January 23, 2003Applicant: Washington UniversityInventors: Charles M. Rice, Alexander A. Kolykhalov
-
Publication number: 20020102540Abstract: The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e.g., for gene therapy of gene vaccines.Type: ApplicationFiled: January 26, 1999Publication date: August 1, 2002Inventors: CHARLES M. RICE, ALEXANDER A. KOLYKHALOV
-
Patent number: 6297003Abstract: The invention relates to the discovery of a novel RNA sequence at the 3′ terminal sequence of hepatitis C virus (HCV) genome RNA. Included in the invention are the 3′ sequence, its complement, and their use for nucleic-acid based diagnostics and for developing and evaluating novel anti-HCV therapies. This sequence element, which is conserved among HCV genotypes, is likely to be essential for viral replication, and required for construction of full-length HCV cDNA clones capable of yielding infectious RNA, progeny virus or replication-competent HCV replicons. Such functional clones are useful tools for evaluation of therapeutic approaches and as substrates for developing candidate attenuated or inactivated HCV derivatives for vaccination against HCV.Type: GrantFiled: July 18, 1997Date of Patent: October 2, 2001Assignee: Washington UniversityInventors: Charles M. Rice, Alexander A. Kolykhalov
-
Patent number: 6127116Abstract: The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e.g., for gene therapy of gene vaccines.Type: GrantFiled: March 4, 1997Date of Patent: October 3, 2000Assignee: Washington UniversityInventors: Charles M. Rice, Alexander A. Kolykhalov
-
Patent number: 5874565Abstract: The invention relates to the discovery of a novel RNA sequence at the 3' terminal sequence of hepatitis C virus (HCV) genome RNA. Included in the invention are the 3' sequence, its complement, and their use for nucleic-acid based diagnostics and for developing and evaluating novel anti-HCV therapies. This sequence element, which is conserved among HCV genotypes, is likely to be essential for viral replication, and required for construction of full-length HCV cDNA clones capable of yielding infections RNA, progeny virus or replication-competent HCV replicons. Such functional clones are useful tools for evaluation of therapeutic approaches and as substrates for developing candidate attenuated or inactivated HCV derivatives for vaccination against HCV.Type: GrantFiled: August 29, 1995Date of Patent: February 23, 1999Assignee: Washington UniversityInventors: Charles M. Rice, Alexander A. Kolykhalov
-
Patent number: 5217879Abstract: Compositions and methods are disclosed for expressing heterologous coding sequences in host cells. The compositions include infectious Sindbis virus RNA molecules containing at least one heterologous coding sequence inserted within the structural region of the Sindbis virus genome. RNA molecules consisting essentially of a Sindbis virus junction region are also provided. Methods utilizing the novel compositions of the present invention to express heterologous coding sequences in transformed host cells are provided. Methods for producing infectious Sindbis virus particles containing infectious Sindbis virus RNA molecules comprising at least one heterologous coding sequence are provided.This invention was made with government support under grant numbers AI24134, AI11377 and AG05681 awarded by the National Institutes of Health. The government has certain rights in the invention.Type: GrantFiled: December 27, 1991Date of Patent: June 8, 1993Assignee: Washington UniversityInventors: Henry V. Huang, Robin Levis, Charles M. Rice, Sondra Schlesinger, Ping Shen, Cheng Xiong
-
Patent number: 4362009Abstract: A yarn stop-motion device for use with a yarn-processing apparatus comprising yarn break-detector means, yarn cutting means and yarn guide means positioned close to each other and combined in a single unit. This device is characterized in that the yarn guide means releases the yarn into the yarn cutting means upon detection of a yarn break by said yarn break-detector means.Type: GrantFiled: August 29, 1980Date of Patent: December 7, 1982Assignee: Akzona IncorporatedInventor: Charles M. Rice